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ABSTRACT
Background: There are sparse data on the utilization rate of implantable cardioverter-
defibrillator (ICD) and its beneficial effects in Korean patients with heart failure with reduced 
left ventricular ejection fraction (LVEF).
Methods: Among 5,625 acute heart failure (AHF) patients from 10 tertiary university 
hospitals across Korea, 485 patients with reassessed LVEF ≤ 35% at least 3 months after the 
index admission were enrolled in this study. The ICD implantation during the follow-up was 
evaluated. Mortality was compared between patients with ICDs and age-, sex-, and follow-up 
duration matched control patients.
Results: Among 485 patients potentially indicated for an ICD for primary prevention, 
only 56 patients (11.5%) underwent ICD implantation during the follow-up. Patients with 
ICD showed a significantly lower all-cause mortality compared with their matched control 
population: adjusted hazard ratio (HR) (95% confidence interval [CI]) = 0.39 (0.16–0.92), 
P = 0.032. The mortality rate was still lower in the ICD group after excluding patients with 
cardiac resynchronization therapy (adjusted HR [95% CI] = 0.09 [0.01–0.63], P = 0.015). 
According to the subgroup analysis for ischemic heart failure, there was a significantly lower 
all-cause mortality in the ICD group than in the no-ICD group (HR [95% CI] = 0.20 [0.06–
0.72], P = 0.013), with a borderline statistical significance (interaction P = 0.069).
Conclusion: Follow-up data of this large, multicenter registry suggests a significant under-
utilization of ICD in Korean heart failure patients with reduced LVEF. Survival analysis implies that 
previously proven survival benefit of ICD in clinical trials could be extrapolated to Korean patients.
Trial Registration: ClinicalTrials.gov Identifier: NCT01389843
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INTRODUCTION
Sudden deaths are common among patients with heart failure with reduced ejection 
fraction (HFrEF), and electrical disturbances, such as ventricular tachycardia, bradycardia, 
and asystole, are considered as major contributors to HFrEF.1 Implantable cardioverter-
defibrillator (ICD) is an effective treatment for both bradycardia and potentially lethal 
ventricular arrhythmias and has proven its beneficial effects on the prevention of sudden 
cardiac deaths in patients with systolic dysfunction.2,3 In the MADIT-II trial, ICD implantation 
reduced sudden arrhythmic death in patients with ischemic heart failure.4 Moreover, it has 
been shown in the SCD-HeFT trial that ICD was better than medical treatment alone with 
respect to reducing mortality in patients with either ischemic or non-ischemic HFrEF.5 
Thus, contemporary guidelines recommend ICD to prevent sudden death in patients with 
symptomatic HF and left ventricular ejection fraction (LVEF) ≤ 35%, after a sufficient trial 
of optimal medications, including angiotensin-converting enzyme inhibitor (ACE-I) and 
beta-blockers.6-10 Although several studies reported that the adherence to these guidelines 
improved the outcomes in Korean heart failure population,11,12 to the best of our knowledge, 
there are sparse data on the status of ICD utilization and its outcomes in this population. 
Therefore, we sought to evaluate the utilization of ICDs and its mortality in Korean systolic 
heart failure patients using Korean prospective multicentre cohort study registry.
METHODS
Study population and Korean acute heart failure (KorAHF) registry
The KorAHF registry was a prospective, multicentre cohort study that enrolled patients 
hospitalized for acute heart failure (AHF) from 10 tertiary university hospitals throughout 
the country from March 2011 to December 2014. Detailed information on the study design 
and its results have been previously reported [ClinicalTrial.gov NCT01389843].13 Patients 
with signs or symptoms of heart failure and either lung congestion, objective findings of left 
ventricular (LV) systolic dysfunction, or structural heart disease were eligible for the study. All 
patients were scheduled for follow-up at least 3 years after the index hospitalization.
Among the total of 5,625 patients with AHF enrolled in the KorAHF registry, those with the 
potential for primary prevention ICD implantation were enrolled in this study. Exclusion 
criteria were as follows: 1) patients who had an ICD implanted before or during the index 
admission, 2) patients who experienced sustained VT during index admission, 3) patients who 
lacked follow-up data on ICD implantation and echocardiography after being discharged from 
index admission. Because the current guidelines recommend optimal medical treatment for 
at least 3 months prior to ICD implantation,2,3 patients showing reduced LVEF (≤ 35%) for at 
least 3 months after the index admission were considered eligible for enrolment in this study. 
A flow chart representing the selection of the study population in Fig. 1.
Follow-up and study endpoints
Patients’ follow-up data were collected by the attending physician, with help of a clinical 
research coordinator, via a web-based system named the Clinical Data Management System 
(iCReaT) from the Korea National Institute of Health (NIH). Follow-up data were collected up 
to 60 months. Details for data collection protocol were described in previous studies.13-15 The 
primary endpoint of the KorAHF registry was the all-cause mortality rate. For the purpose 
of this study, we investigated the rate of ICD implantation among those considered eligible 
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for ICD implantation after the discharge from the index admission. And the post-discharge 
all-cause mortalities were compared between the patients with (ICD group) and without ICD 
implantation (no-ICD group).
Analysis in matched population
Additional matched analysis was performed to address the issue of selection bias. First, for 
each patient from the ICD group, age- (± 2 years tolerance) and sex-matched patients were 
screened from the no-ICD group. If the follow-up duration of the patient in the no-ICD group 
was shorter than the time to ICD insertion of the corresponding patient in the ICD group, the 
patient was excluded. Then individually matched control was randomly selected among these 
candidates in 1:1 ratio. One patient in the ICD group was excluded from this process due to 
the lack of matched patient with comparable follow-up duration.
Statistical analysis
Data are presented as the numbers and frequencies for categorical variables and as the means 
± standard deviations for continuous variables. To make comparisons among groups, the 
χ2 test (or Fisher's exact test) was used for categorical variables, and the unpaired Student's 
t-test (or Mann-Whitney U test) was used for continuous variables. Kaplan–Meier curves were 
plotted and compared, using the log-rank test for evaluation of post-discharge outcomes. 
A multivariable Cox proportional-hazards regression models were used to determine the 
independent effect of ICD insertion time on post-discharge outcomes, respectively. Variables 
found to be statistically significant (P < 0.1) in the univariate analysis were included in the 
multivariable model, except for variables with > 10% missing values or variables with a close 
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5,625 patients hospitalized 
for AHF syndrome in KorAHF registry
1,901 patients with
data on follow-up EchoCG and ICD insertion
113 patients with prior ICD insertion
36 sustained VT during index admission
106 ICD insertion during index admission
2,594 no data on ICD insertion during follow-up
3,771 no available data on follow-up EchoCG
485 patients LVEF ≤ 35%
(> 3 mon after index admission)
56 ICD implanted 429 no ICD implantation
55 ICD implanted 55 no ICD implantation
Matching by age, sex, and follow-up duration
Fig. 1. Flowchart of the study population. 
KorAHF = The Korean Acute Heart Failure registry, ICD = implantable cardioverter-defibrillator, EchoCG = 
echocardiography, LVEF = left ventricular ejection fraction.
association with other clinical variables. A two-sided probability value < 0.05 was considered 
significant. Statistical tests were performed using R programming version 3.6.0 (The R 
Foundation for Statistical Computing, Vienna, Austria, http://www.R-project.org).
Ethics statement
The study protocol was approved by the Institutional Review Board (IRB) at each hospital and 
complied with the Declaration of Helsinki, and the requirement for written informed consent 
was waived (Seoul National University Bundang Hospital, IRB No. B-1104/125-014).
RESULT
Utilization of ICD in study population
Among the 485 patients whose follow-up echocardiography showed sustained reduced left 
ventricular systolic function (LVEF ≤ 35%), only 56 patients (11.5%) underwent ICD implantation 
during the follow-up. The median follow-up 1,046 days (interquartile range [IQR], 618–1,357 
days), the median time to ICD implant was 539 days (IQR, 273–832). The median time to 
follow-up echocardiography from the index admission was 329 days (IQR, 211–413). Cardiac 
resynchronization therapy defibrillator (CRT-D) was used in 35.7% (20/56) of the ICD group, 
while CRT pacemaker (CRT-P) was used in only 0.2% (1/429) of the no-ICD group. The clinical 
characteristics according to the insertion of ICD during follow-up are provided in Table 1. 
Younger age (ICD vs. no ICD group; 62.9 ± 13.0 vs. 68.7 ± 13.9, P = 0.003), male sex (82.1% vs. 
60.1%, P = 0.002), and more depressed LVEF (23.1 ± 7.7% vs. 27.9 ± 9.8%, P < 0.001) at the time 
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Table 1. Baseline characteristics and utilization of ICD
Characteristics ICD implant (n = 56) No ICD (n = 429) P value
Age, yr 62.9 ± 13.0 68.7 ± 13.9 0.003
Male 46 (82.1) 258 (60.1) 0.002
BMI 24.7 ± 4.1 23.2 ± 3.6 0.003
Hypertension 29 (51.8) 252 (58.7) 0.397
Diabetes mellitus 31 (55.4) 195 (45.5) 0.210
Ischemic heart disease 20 (35.7) 176 (41.0) 0.537
Valvular heart disease 3 (5.4) 46 (10.7) 0.309
Cerebrovascular disease 10 (17.9) 54 (12.6) 0.376
Chronic kidney disease 6 (10.7) 82 (19.1) 0.177
Malignancy 3 (5.4) 36 (8.4) 0.600
COPD 3 (5.4) 48 (11.2) 0.269
De novo heart failure 27 (48.2) 165 (38.5) 0.208
AF 9 (16.1) 104 (24.2) 0.233
Previous HF admission 22 (39.3) 190 (44.3) 0.571
ICU admission 26 (46.4) 204 (47.0) 1.000
Mechanical ventilation 6 (10.7) 43 (10.0) 1.000
LVEF, % 23.1 ± 7.7 27.9 ± 9.8 < 0.001
LA dimension, mm 47.9 ± 5.6 48.4 ± 9.1 0.536
Hemoglobin, g/dL 13.6 ± 2.2 12.4 ± 2.2 < 0.001
Serum creatinine, mg/dL 1.5 ± 1.2 1.6 ± 1.6 0.466
Discharge medication
ACEi or ARB, % 50 (89.3) 328 (76.5) 0.045
Beta-blocker, % 36 (64.3) 215 (50.1) 0.064
CRT 20 (35.7) 1 (0.2) < 0.001
Time to f/u echocardiography 324 ± 120 321 ± 136 0.878
Data are expressed as mean ± standard deviation or number (%).
ICD = indicates implantable cardioverter-defibrillator, BMI = body mass index, COPD = chronic obstructive 
pulmonary disease, AF = atrial fibrillation, HF = heart failure, ICU = intensive care unit, LVEF = left ventricular 
ejection fraction, LA = left atrium, ACEi = angiotensin-converting-enzyme inhibitors, ARB = angiotensin receptor 
blocker, CRT = cardiac resynchronization therapy.
of index admission were correlated with future ICD implantation. The prescription rate of beta-
blocker or renin-angiotensin system inhibitor (RAS-inhibitor) at the time of discharge tended to 
be higher in patients who received ICD implantation (ICD vs. no-ICD group; 64.3% vs. 50.1%, 
P = 0.064 for beta-blocker, 89.3% vs. 76.5%, P = 0.045 for RAS-inhibitor). The etiology of heart 
failure and proportion of other comorbidities, such as hypertension, diabetes, cerebrovascular 
disease, and malignancy, were not different between groups.
Predictors for mortality during follow-up
The predictors for all-cause mortality were screened in the study population. These are 
presented in Table 2. ICD implantation was significantly correlated with favorable mortality 
outcome in univariate analysis, and also in multivariate analysis (Table 2). The hazard ratio 
was 0.30 (95% confidence interval [CI], 0.16–0.59; P < 0.001) and 0.43 (95% CI, 0.22–0.82; 
P = 0.011), before and after the adjustment for other variables, respectively. Older age, 
female sex, lower body mass index (BMI), hypertension, ischemic heart disease, chronic 
kidney disease, ADHF, previous history of HF admission, higher baseline LVEF, lower 
hemoglobin, higher serum creatinine level, no prescribed ACEi or ARB, and beta-blocker 
were also significantly correlated with the higher all-cause mortality in univariate analysis. 
In multivariate analysis, age, BMI, chronic kidney disease, previous HF admission, and no 
prescribed beta-blocker were significantly correlated with mortality.
Comparison of mortality in matched population
The baseline characteristics for the 1:1 matched population are presented in Table 3. 
All unmatched variables also became comparable between the ICD and no-ICD groups. 
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Table 2. Predictors for all-cause mortality
Variables Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
ICD insertion 0.32 (0.17–0.60) < 0.001 0.43 (0.22–0.82) 0.011
CRT insertion 0.57 (0.25–1.29) 0.177
Age 1.04 (1.03–1.05) < 0.001 1.03 (1.01–1.04) 0.001
Male 0.74 (0.56–0.99) 0.043 1.05 (0.76–1.44) 0.758
BMI 0.93 (0.90–0.97) 0.001 0.95 (0.91–0.99) 0.022
Hypertension 1.63 (1.21–2.19) 0.001 1.23 (0.89–1.70) 0.201
Diabetes 1.26 (0.95–1.67) 0.110 1.24 (0.91–1.71) 0.179
Ischemic heart disease 1.35 (1.02–1.79) 0.038 0.91 (0.67–1.25) 0.567
Valvular heart disease 0.70 (0.41–1.18) 0.179
COPD 1.51 (0.99–2.30) 0.056 1.13 (0.73–1.75) 0.577
Cerebrovascular disease 1.27 (0.86 –1.89) 0.227
Chronic kidney disease 2.59 (1.90–3.52) < 0.001 2.07 (1.39–3.08) < 0.001
Malignancy 1.31 (0.80–2.12) 0.281
ADHF (vs. de novo) 1.66 (1.22–2.25) 0.001 0.91 (0.57–1.45) 0.692
Previous HF admission 1.83 (1.38–2.44) < 0.001 1.76 (1.15–2.68) 0.009
Atrial fibrillation 1.04 (0.75–1.46) 0.797
LVEF 1.02 (1.00–1.03) 0.023 1.00 (0.98–1.02) 0.987
LA 1.01 (0.99–1.03) 0.237
Hemoglobin 0.86 (0.81–0.92) < 0.001 1.02 (0.91–1.06) 0.632
Creatinine 1.07 (1.01–1.13) 0.027 0.99 (0.88–1.11) 0.884
ICU admission 1.04 (0.79–1.39) 0.764
Mechanical ventilation 1.29 (0.83–1.99) 0.255
ACEi or ARBa 0.63 (0.46–0.87) 0.005 0.88 (0.63–1.23) 0.440
Beta-blockera 0.50 (0.38–0.67) < 0.001 0.56 (0.41–0.75) < 0.001
HR = hazard ratio, CI = confidence interval, ICD = indicates implantable cardioverter-defibrillator, CRT = cardiac resynchronization therapy, BMI = body mass 
index, COPD = chronic obstructive pulmonary disease, ADHF = acute decompensated heart failure, HF = heart failure, LVEF = left ventricular ejection fraction, LA 
= left atrium, ICU = intensive care unit, ACEi = angiotensin-converting-enzyme inhibitors, ARB = angiotensin receptor blocker.
aMedications prescribed at discharge from index admission.
Excluding the 20 CRT-D patients and their paired no-ICD group patients, the serum 
creatinine level was significantly correlated with ICD implantation during the follow-up 
period. The presence of chronic kidney disease and application of mechanical ventilation 
during the index admission also tended to be correlated with ICD insertion. After matching, 
Cox proportional survival analysis revealed that mortality was still significantly lower in the 
ICD group. HR was 0.45 (95% CI, 0.20–0.98; P = 0.044) and 0.39 (95% CI, 0.16–0.92; P = 
0.032) before and after adjustment for other variables, respectively (Table 4). After excluding 
20 CRT-D related pairs, the mortality rate was still lower in the ICD group compared with the 
no-ICD group before (HR [95% CI] = 0.30 [0.10–0.95], P = 0.041) and after adjustments (HR 
[95% CI] = 0.09 [0.01–0.63], P = 0.015). Kaplan-Meier estimates of survival in the overall and 
matched study population are shown in Fig. 2.
Subgroup analysis
We performed exploratory subgroup analysis in the matched study population. In the 
ischemic heart failure subgroup, the all-cause mortality rate during the follow-up period 
was significantly lower in the ICD insertion group than in the ICD non-insertion group (HR 
[95% CI] = 0.20 [0.06–0.72], P = 0.013), with a borderline interaction P value (interaction P 
= 0.069). Other than the etiology of HF, the effects of ICD insertion on mortality were not 
significantly different according to sex, diabetes mellitus, hypertension, chronic kidney 
disease, atrial fibrillation, or type of HF (Table 5).
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Table 3. Baseline characteristics in matched population
Characteristics Including CRT-D Excluding CRT-D
ICD implant (n = 55) No ICD (n = 55) P value ICD implant (n = 35) No ICD (n = 35) P value
Age, yr 63.0 ± 13.1 62.9 ± 12.9 0.965 60.1 ± 13.3 60.2 ± 13.1 0.957
Male 46 (83.6) 46 (83.6) 1.000 29 (82.9) 29 (82.9) 1.000
BMI 24.8 ± 4.1 24.7 ± 3.9 0.896 24.6 ± 4.0 23.6 ± 2.3 0.508
Hypertension 28 (50.9) 31 (56.4) 0.702 17 (48.6) 19 (54.3) 0.811
Diabetes mellitus 30 (54.5) 29 (52.7) 1.000 19 (54.3) 22 (62.9) 0.627
Ischemic heart disease 20 (36.4) 21 (38.2) 1.000 11 (31.4) 9 (25.7) 0.791
Valvular heart disease 3 (5.5) 4 (7.3) 1.000 2 (5.7) 3 (8.6) 1.000
Cerebrovascular disease 10 (18.2) 9 (16.4) 1.000 6 (17.1) 7 (20.0) 1.000
Chronic kidney disease 5 (9.1) 9 (16.4) 0.391 1 (2.9) 7 (20.0) 0.060
Malignancy 3 (5.5) 4 (7.3) 1.000 2 (5.7) 2 (5.7) 1.000
COPD 3 (5.5) 8 (14.5) 0.204 1 (2.9) 3 (8.6) 0.607
De novo heart failure 27 (49.1) 21 (38.2) 0.336 19 (54.3) 12 (34.3) 0.149
AF 9 (16.4) 16 (29.1) 0.172 9 (31.4) 11 (31.4) 0.791
Previous HF admission 22 (40.0) 25 (40.0) 0.700 12 (34.3) 15 (42.9) 0.623
ICU admission 26 (47.3) 29 (52.7) 0.703 16 (45.7) 19 (54.3) 0.633
Mechanical Ventilation 6 (10.9) 4 (7.3) 0.740 5 (14.3) 0 (0.0) 0.063
LVEF (baseline), % 22.8 ± 7.6 25.1 ± 9.3 0.181 21.8 ± 7.2 23.0 ± 9.0 0.524
LA dimension, mm 47.9 ± 5.7 50.1 ± 8.7 0.117 48.1 ± 5.5 50.2 ± 7.9 0.199
Hemoglobin, g/dL 13.7 ± 2.2 13.3 ± 2.6 0.415 13.9 ± 2.3 13.5 ± 2.7 0.477
Serum creatinine, mg/dL 1.4 ± 1.0 1.7 ± 1.2 0.193 1.2 ± 0.8 1.7 ± 1.3 0.038
Discharge medication
ACEi or ARB, % 50 (90.9) 46 (83.6) 0.391 34 (97.1) 29 (82.9) 0.111
Beta-blocker, % 36 (65.5) 32 (58.2) 0.556 26 (74.3) 21 (60.0) 0.309
CRT 20 (36.4) 0 (0) < 0.001 NA NA NA
Data are expressed as mean ± standard deviation or number (%).
CRT = cardiac resynchronization therapy, ICD = indicates implantable cardioverter-defibrillator, BMI = body mass index, COPD = chronic obstructive pulmonary 
disease, AF = atrial fibrillation, HF = heart failure, ICU = intensive care unit, LVEF = left ventricular ejection fraction, LA = left atrium, ACEi = angiotensin-
converting-enzyme inhibitors, ARB = angiotensin receptor blocker.
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Table 4. Predictors for all-cause mortality in matched population
Variables Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
ICD insertion 0.45 (0.20–0.98) 0.044 0.39 (0.16–0.92) 0.032
CRT insertion 1.15 (0.46–2.84) 0.769
Age 1.06 (1.02–1.10) 0.005 1.12 (1.04–1.20) 0.001
Male 0.36 (0.16–0.83) 0.016 0.54 (0.17–1.70) 0.290
BMI 0.91 (0.80–1.04) 0.149 0.95 (0.84–1.07) 0.381
Hypertension 1.16 (0.54–2.47) 0.708 2.95 (1.10–7.91) 0.031
Diabetes 1.91 (0.86–4.26) 0.115 1.52 (0.58–3.95) 0.392
Ischemic heart disease 1.79 (0.84–3.84) 0.132 0.86 (0.63–1.18) 0.358
Valvular heart disease NA NA
COPD 3.04 (1.05–8.82) 0.041 2.82 (0.72–11.0) 0.136
Cerebrovascular disease 1.92 (0.77–4.77) 0.160
Chronic kidney disease 3.12 (1.32–7.40) 0.010 1.49 (0.30–7.32) 0.622
Malignancy 0.56 (0.08–4.11) 0.566
ADHF (vs. de novo) 2.32 (0.98–5.49) 0.056 2.21 (0.44–11.2) 0.338
Previous HF admission 2.14 (0.99–4.62) 0.052 1.71 (0.42–6.95) 0.454
Atrial fibrillation 0.91 (0.37–2.27) 0.841
LVEF (baseline) 1.00 (0.96–1.04) 0.914 0.97 (0.92–1.02) 0.224
LA 1.02 (0.96–1.09) 0.440
Hemoglobin 0.79 (0.67–0.92) 0.003 1.13 (0.93–1.36) 0.211
Creatinine 1.39 (1.07–1.80) 0.013 1.15 (0.69–1.91) 0.588
ICU admission 0.78 (0.36–1.67) 0.523
Mechanical ventilation 1.92 (0.66–5.56) 0.229
ACEi or ARBa 0.35 (0.14–0.88) 0.025 0.77 (0.23–2.52) 0.661
Beta-blockera 0.49 (0.23–1.05) 0.066 0.30 (0.12–0.73) 0.008
HR = hazard ratio, CI = confidence interval, ICD = indicates implantable cardioverter-defibrillator, CRT = cardiac resynchronization therapy, BMI = body mass 
index, COPD = chronic obstructive pulmonary disease, ADHF = acute decompensated heart failure, HF = heart failure, LVEF = left ventricular ejection fraction, LA 
= left atrium, ICU = intensive care unit, ACEi = angiotensin-converting-enzyme inhibitors, ARB = angiotensin receptor blocker.












































Adjusted HR (95% CI)
0.09 (0.01–0.63)
P = 0.015
Fig. 2. All-cause mortality according to the ICD implantation during follow-up. (A) In the matched study population, and (B) after excluding patients with CRT-D 
and their matched controls. 
ICD = implantable cardioverter-defibrillator, HR = hazard ratio, CI = confidence interval.
DISCUSSION
In patients with sustained LV dysfunction, ICD implantation is recommended for the 
improvement of survival. The aims of this study were 1) to speculate the utilization rate of 
ICDs in Korean heart failure patients and 2) to evaluate the efficacy of ICDs in Korean heart 
failure patients, using a prospective large multi-center KorAHF registry. Among the 5,625 
KorAHF patients, there were 485 identifiable ICD candidates for primary prevention based 
on their follow-up transthoracic echocardiography. Among them, only 56 (11.5%) patients 
underwent ICD implantation, implying under-utilization of ICDs in Korean LV dysfunction 
heart failure patients. In the matched analysis, all-cause mortality was significantly lower in 
patients with ICD implantation than in patients without ICD implantation. This suggests 
that there is indeed a beneficial effect of ICD in patients with advanced HF. This is in line 
with previous randomized trials and their meta-analysis conducted in western countries,16-18 
which could be extrapolated to Korean patients.
There were several studies reporting the primary prevention ICD implantation rates in 
patients with advanced heart failure. The TRIUMPH registry data demonstrated that among 
the patients who survived myocardial infarction (MI) and had LVEF < 40% at discharge, 
only 35% underwent LVEF reassessment at 6 months and 2.4% received an ICD at 1 year.19 
More recently, Pokorney et al.20 reviewed Medicare-insured patients with EF ≤ 35% during 
index myocardial infarction admission and reported that among those who underwent EF 
reassessment after discharge from the index admission, only 11% received an ICD within 1 
year. In the Swedish Heart Failure Registry, ICD for primary prevention was also underused 
(ICD implantation rate 9.6%).21 Percent of LVEF improvement was not presented in these 
two papers. There was a recent report on the increasing annual number of ICD implantation 
in Korea, but the utilization rates among eligible population was not considered in this 
paper.22 The current study showed that the ICD implantation rate in Korean heart failure 
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Table 5. HRs for mortality with ICD insertion in subgroups of matched population
Variables No. of patients HR (95% CI) P value Interaction P value
Etiology of HF 0.069
Ischemic 41 0.20 (0.06–0.72) 0.013
Non-ischemic 69 0.81 (0.29–2.29) 0.680
Sex 0.785
Male 92 0.46 (0.19–1.08) 0.074
Female 18 0.34 (0.06–1.74) 0.195
Diabetes mellitus 0.897
Yes 56 0.40 (0.15–1.04) 0.059
No 54 0.43 (0.11–1.76) 0.243
Hypertension 0.300
Yes 58 0.67 (0.23–1.93) 0.455
No 52 0.25 (0.08–0.84) 0.025
Chronic kidney disease 0.209
Yes 14 1.09 (0.24–4.96) 0.914
No 96 0.36 (0.15–0.87) 0.023
Atrial fibrillation 0.719
Yes 28 0.30 (0.03–2.58) 0.273
No 85 0.44 (0.19–1.01) 0.052
Type of heart failure 0.271
De novo 48 0.22 (0.04–1.08) 0.062
ADHF 62 0.60 (0.25–1.44) 0.251
Hazard ratios for all-cause mortality associated with ICD implantation.
HR = hazard ratio, ICD = indicates implantable cardioverter-defibrillator, CI = confidence interval, HF = heart 
failure, ADHF = acute decompensated heart failure.
patients eligible for primary prevention ICD was about 11.5% during the overall follow-up. 
The ICD insertion rate at 1-year follow-up was lower than this, which was 6.6%. The ICD 
insertion rate in real-world practice might be even lower, considering that the KorAHF 
only enrolled patients from 10 major tertiary hospitals in Korea. In addition, it should be 
considered that our study only enrolled patients who were considered eligible for an ICD. 
Eligibility for an ICD was based on the echocardiographic results, at least 3 months apart 
from the index admission. Optimal medical treatment was assumed during this period, 
because the hospitals participating in this KorAHF study were tertiary hospitals with 
cardiologists specialized in heart failure treatment. In the subgroup of patients who were 
prescribed both RAS inhibitors and beta-blockers at discharge, ICD insertion rates were 9.1% 
at 1-year follow-up and 16.7% during overall follow-up, still demonstrating low utilization 
of ICDs. The low rate of ICD utilization can be attributed to factors from both patients and 
physicians. In this study, young age, male sex, and higher BMI were correlated with future 
ICD implantation. Other than underlying diseases, financial status, physicians’ attitude and 
patients’ preference for ICDs may have also influenced the utilization of ICD, although such 
data were not available. Several previous studies suggested that there may be a correlation 
between regional supply of cardiologists or electrophysiologists and ICD usage.23-25 However, 
at least for our study, such correlation was not the cause of low ICD usage, because hospitals 
participating in KorAHF were all tertiary hospitals with a plethora of qualified cardiologists 
and electrophysiologists. Referral to an ICD interventionist may be another hindering step. 
Gupta et al.26 demonstrated that electronic medical record based reminders improved 
both ICD discussion rate (44% to 67%) and implantation rate (2% to 24%), suggesting that 
improvement in this referring step can make a real difference in the utilization of ICD.
The beneficial effects of ICDs in patients with advanced systolic heart failure have not 
sufficiently been addressed in Asian patients, especially in Korean patients.4,5,16-18 Although 
there have been a few studies involving Korean patients with respect to ICD implantation,27-30 
they present the outcomes in a single-arm observational environment, without any comparison 
to a control population. The present study enrolled patients with long-lasting systolic heart 
failure with ICD implantation and compared them against their match patients without ICD 
implantation. To the best of our knowledge, this is the first study demonstrating the benefits 
of ICDs in Korean patients with systolic heart failure. In the SCD-HeFT study, the benefit of 
ICD on the prevention of mortality was shown in patients with systolic heart failure, either 
ischemic or non-ischemic.5 However, a recent DANISH trial raised questions about the 
usefulness of ICD in non-ischemic cardiomyopathy.31 The subgroup analysis of the present 
study also demonstrated a trend of differential benefits of ICD according to the etiology of 
HF. The mortality of the ICD group was significantly lower than that of the control group in 
the ischemic HF subgroup (HR [95% CI] = 0.20 [0.06–0.72], P = 0.013), while the mortalities 
were comparable between the groups in the non-ischemic HF subgroup (HR [95% CI] = 0.81 
[0.29–2.29], P = 0.680). Interaction P value was borderline (0.069). (Table 5) The benefits of 
ICD in patients receiving CRT have recently been questioned.32 To address the confounding 
effect of CRT, additional survival analysis was performed after excluding CRT-D patients and 
their paired control patients. The mortality was still lower in the ICD group than in the control 
group (Fig. 2B), suggesting that there is a clear beneficial effect of ICDs in the study population.
This study has several limitations. This is a prospective cohort study and there could be 
unaddressed biases such as sarcopenia in comparing the outcomes between the ICD and 
control groups. However, randomized trials there should be ethical issues in conduction 
randomized trials that evaluate the benefits of ICDs in this population. The matching process 
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was adopted in this study in efforts to address this issue to some degree, though matching 
variables were limited due to the small number of the eligible patients. At least, there was 
no significant difference between the matched groups regarding the baseline characteristics 
including discharge medications. Information on prescription of the new drugs such as 
angiotensin receptor-neprilysin inhibitor or sodium-glucose cotransporter-2 inhibitor was 
not collected in the KorAHF registry. Mortality data were collected with assistance from the 
National Death Records, and survival analysis on specific cause of death, such as sudden 
cardiac death, was not feasible. After narrowing down the study population, the size of 
the matched population was rather underpowered to validate the effects of ICD in various 
subgroups. It was not possible to clarify the reasons for the low ICD utilization in this study.
In conclusion, follow-up data of this large multicenter KorAHF registry suggests a significant 
under-utilization of ICD in Korean heart failure patients with reduced LVEF. Survival 
analysis implies that benefits of ICD proven in clinical trials from western countries could be 
extrapolated to Korean patients.
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